The tumor protein 53 (TP53) tumor suppressor gene is the most frequently somatically altered gene in human cancers. Here we show expression of N-Myc down-regulated gene 1 (NDRG1) is induced by p53 during physiologic low proliferative states, and mediates centrosome homeostasis, thus maintaining genome stability. When placed in physiologic low-proliferating conditions, human TP53 null cells fail to increase expression of NDRG1 compared with isogenic wild-type controls and TP53 R248W knockin cells. Overexpression and RNA interference studies demonstrate that NDRG1 regulates centrosome number and amplification. Mechanistically, NDRG1 physically associates with γ-tubulin, a key component of the centrosome, with reduced association in p53 null cells. Strikingly, TP53 homozygous loss was mutually exclusive of NDRG1 overexpression in over 96% of human cancers, supporting the broad applicability of these results. Our study elucidates a mechanism of how TP53 loss leads to abnormal centrosome numbers and genomic instability mediated by NDRG1.
NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability Edited by Curtis C. Harris, National Cancer Institute NIH, Bethesda, MD, and accepted by the Editorial Board August 07, 2015 (received for review February 22, 2015) The tumor protein 53 (TP53) tumor suppressor gene is the most frequently somatically altered gene in human cancers. Here we show expression of N-Myc down-regulated gene 1 (NDRG1) is induced by p53 during physiologic low proliferative states, and mediates centrosome homeostasis, thus maintaining genome stability. When placed in physiologic low-proliferating conditions, human TP53 null cells fail to increase expression of NDRG1 compared with isogenic wild-type controls and TP53 R248W knockin cells. Overexpression and RNA interference studies demonstrate that NDRG1 regulates centrosome number and amplification. Mechanistically, NDRG1 physically associates with γ-tubulin, a key component of the centrosome, with reduced association in p53 null cells. Strikingly, TP53 homozygous loss was mutually exclusive of NDRG1 overexpression in over 96% of human cancers, supporting the broad applicability of these results. Our study elucidates a mechanism of how TP53 loss leads to abnormal centrosome numbers and genomic instability mediated by NDRG1.
p53 | NDRG1 | centrosomes | genomic instability | proliferation T umor protein 53 (TP53) encodes p53 and is one of the most well-studied tumor suppressor genes. Among its many functions, p53 plays a central role in apoptosis, cell cycle arrest, and maintaining genomic integrity (1) (2) (3) . Normally, p53 acts as a critical cellular checkpoint monitor in response to stress such as DNA damage. This function prevents cells with aberrant or damaged DNA from proceeding through the cell cycle, allowing time to correct damaged DNA or induce apoptosis if DNA cannot be repaired. This critical role thus prevents cells with altered DNA from inappropriate cell division.
Although TP53 is one of the most well described tumor suppressor genes, the mechanisms of many of its functions have not been fully elucidated. In particular, p53's role in maintaining genomic stability remains incompletely understood. It is well known that in the absence of normal p53 function, downstream effectors such as p21 are crippled and can no longer prevent aberrant cell cycling in response to DNA damage (4). However, this fact suggests that lack of p53 function is not directly responsible for genome instability, but instead that damaged DNA is allowed to inappropriately propagate through cell division if p53 function is absent (5) . This mechanism would also suggest that increased cell cycling would produce more opportunities for DNA errors, and thus the absence of p53 function in this instance would allow cells with altered DNA to propagate rapidly, leading to an increased potential for producing oncogenic changes. However, many human cancers have low proliferation rates, yet still display genomic instability and aneuploidy (6) . In addition, seminal studies have demonstrated that loss of TP53 has distinct functional consequences compared with TP53 missense mutations (7, 8) , yet both types of alterations are found in human cancers. Thus, mechanisms of how genomic instability and aneuploidy arise may differ in cancer cells with homozygous loss of TP53 versus those with heterozygous missense mutations.
In this study, we sought to elucidate the mechanism of genomic instability specifically associated with TP53 loss. We approached this via genome editing using the noncancerous human breast epithelial cell line, MCF10A, and comparing p53 null cells to isogenic cells harboring a common TP53 missense mutation, R248W. Relative to control and TP53 missense cell lines, we determined that p53 loss leads to increased genomic instability, which is associated with the presence of supernumerary centrosomes, a described mechanism of instability resulting in aneuploidy (9) . Using an unbiased proteomic screen, we identified NDRG1 as differentially up-regulated in control and TP53 missense cell lines compared with TP53 null cells, but only under physiologic lowproliferation conditions. We show that forced expression of NDRG1 reduced abnormal centrosome numbers in MCF10A and HCT116 p53 null cells, whereas knockdown of N-Myc downregulated gene 1 (NDRG1) by RNA interference (RNAi) in TP53 wild-type parental cells led to supernumerary centrosomes. Using
Significance
The mechanism of how loss of the tumor suppressor p53 can lead to genomic instability is not fully understood. This study demonstrates that under physiologic low levels of proliferation, homozygous loss of tumor protein 53 (TP53) via genome editing, but not common p53 missense mutations, results in an inability to increase expression of N-Myc down-regulated gene 1 (NDRG1). In turn, failure to upregulate NDRG1 protein under low proliferative states leads to supernumerary centrosome formation, a known mechanism of aneuploidy. These results provide a mechanistic link between loss of TP53, proliferation, NDRG1, and genomic instability and help explain how cells with a low proliferative index and p53 loss can acquire additional genetic alterations that lead to cancer.
proximity ligation assays, we found that NDRG1 associates with γ-tubulin, a key component of centrosomes, thus providing a mechanistic link between p53, NDRG1, and centrosome homeostasis. In silico analysis of multiple human tumor samples revealed that homozygous loss of TP53 is nearly mutually exclusive with NDRG1 overexpression, strongly corroborating our in vitro data to actual human cancers. Taken together, our results provide a previously unidentified model, suggesting that under conditions of physiologic low proliferation, p53 up-regulates NDRG1 expression, altering its interaction with γ-tubulin, thereby regulating centrosome homeostasis in a precise fashion. In cells with loss of p53, NDRG1 expression is not increased during cellular arrest and/or low proliferative states, allowing for supernumerary centrosome numbers, which results in genomic instability and aneuploidy.
Results

Distinct Phenotypes of p53 Null Versus p53 R248W Heterozygous
Missense Gene-Targeted Cell Lines. We have previously described the generation of TP53 null clones in the MCF10A cell line using genome editing with recombinant adeno-associated virus (rAAV) (10) . MCF10A is a spontaneously immortalized nontumorigenic human breast epithelial cell line that is ideal for genome editing studies given its relatively normal karyotype, genome stability, and lack of oncogenic mutations (11) . For these studies, we used two independent p53 null clones: 3b and 4b, hereafter designated KO1 and KO2. To characterize phenotypes unique to p53 loss versus common missense mutations, we used rAAV genome editing to "knock in" a common TP53 heterozygous missense mutation, R248W, using a previously described vector (12) ( SI Appendix, Fig.  S1A ). Two independently derived clones were isolated and confirmed as having a single site of integration and equivalent allelic expression of mutant and wild-type alleles (SI Appendix, Fig. S1B ). These were designated KI1 and KI2 and used for further studies.
MCF10A cells require exogenous growth factors, including epidermal growth factor (EGF) for continued proliferation, and indeed, growth factor independence is a hallmark of a transformed phenotype. Prior work in our laboratory and others demonstrated that introduction of oncogenic mutations in MCF10A by gene targeting or transgene expression leads to EGF independent growth (13, 14) . In addition, our past studies demonstrated that p53 null cells could propagate without EGF in 2% (vol/vol) charcoal dextran-treated serum (10) . However, for the current studies, we used physiologic concentrations of EGF (0.2 ng/mL), as we have previously shown that this dose of EGF allows for comparison with parental MCF10A cells, which are EGF dependent, but can proliferate slowly at this concentration (13) . Using physiologic doses of EGF also allows for pathway signaling and drug sensitivity studies that can be masked by high proliferation rates due to hyperactivation of PI3 kinase and MAP kinase pathways when using the historic media formulation for tissue culture maintenance of 20 ng/mL EGF (13) .
Under physiologic doses of EGF, p53 KO cells proliferated more slowly compared with the MCF10A cells and p53 KI cells (SI Appendix, Fig. S2A ). Because these cells are aneuploid (10) , this is consistent with observations that in noncancerous cells, aneuploidy can lead to reduced cell proliferation (15) . However, . NDRG1 gene expression is regulated by TP53 and is increased in physiologic low-proliferation culture conditions. (A) Reverse phase protein array (RPPA) was carried out using MCF10A, TP53 KI (KI1 and KI2) and TP53 KO (KO1 and KO2) cell line lysates after culture in physiologic EGF conditions. Phosphorylated NDRG1 (pNDRG1) exhibited a five-to sixfold increase in MCF10A and TP53 KI cell lines. (B) RPPA expression levels were confirmed with Western blot analysis using antibodies against pNDRG1 and total NDRG1 in 0.2 ng/mL and 20 ng/mL EGF conditions. GAPDH is shown as a loading control. (C) Cell lysates were harvested from MCF10A and TP53 derivative cell lines after culture in 0.2 ng/mL and 20 ng/mL EGF conditions as described in SI Appendix, SI Materials and Methods and used for Western blot with an anti-p53 antibody. GAPDH is shown as a loading control. (D) Chromatin immunoprecipitation (ChIP) of MCF10A and TP53-derivative cell lines cultured in 0.2 ng/mL and 20 ng/mL EGF concentrations using an anti-p53 antibody and quantitative real-time PCR primers was carried out as described in SI Appendix, SI Materials and Methods.
Results show relative p53 binding of the NDRG1 promoter in 0.2 ng/mL and 20 ng/mL EGF conditions, and results are the average of three independent experiments with samples run in triplicate. Error bars represent SEM. ***P < 0.001.
in elevated levels of EGF, p53 KO cells demonstrated similar proliferation rates to parental MCF10A cells, consistent with our prior report (10) (SI Appendix, Fig. S2B ). Interestingly, p53 KI cells demonstrated increased proliferation in high EGF culture conditions, consistent with studies demonstrating gain of function with TP53 missense mutations (7) . In accord with these results, colony formation assays also demonstrated no appreciable difference between p53 KO clones and parental cells, but p53 KI clones had a significantly increased number of colonies in limiting dilution assays (SI Appendix, Fig. S2C ). TP53 is also thought to play a role in preventing genomic instability. Although knockout of TP53 by genome editing was not shown to influence chromosomal instability (CIN) or lead to aneuploidy in the HCT116 colorectal cancer cell line, p53 null HCT116 do have an increased rate of tetraploidy (16) , suggesting possible effects of genome instability due to p53 loss. In contrast, our past work demonstrated that gene targeting of MCF10A cells did lead to aneuploidy, though formal CIN analysis was not performed in those studies (10) . We therefore performed fluorescent in situ hybridization (FISH) with multiple probes and carried out a CIN analysis with our cell line panel. As shown in Fig. 1 A and B, one of two p53 KO cells demonstrated a statistically significant elevated rate of CIN compared with parental MCF10A cells and p53 KI cells. It should be noted that KO2 has an increase in chromosomal alterations/aneuploidy relative to KO1 (10) . Thus, it is likely that additional alterations in KO2 account for a high degree of CIN, possibly in mitotic spindle check point genes. In agreement with this result, using Matrigel and soft agar assays, only p53 KO2 demonstrated aberrant acini and colony formation, suggesting this effect was mediated by other genomic changes present in this clone (SI Appendix, Fig. S3 ). Another known mechanism of genomic instability is supernumerary centrosomes leading to abnormal chromosomal segregation and aneuploidy (9, 17) . To determine whether altered centrosome homeostasis was present in p53 null cells, we stained for γ-tubulin. As seen in Fig. 1 C and D, increased centrosomes were seen only in p53 KO cells and not in parental or p53 KI cell lines. This difference was statistically significant for both p53 KO clones and suggests a direct effect of p53 loss. Interestingly, supernumerary centrosomes in p53 KO cells were seen predominantly in physiologic EGF conditions. However, under high proliferative conditions with 20 ng/mL EGF, cells displayed increased cytoplasmic fluorescence, which was marked in TP53 KO cells (Fig. 1E) . Although there did not appear to be an appreciable difference in centrosome numbers between parental, TP53 KI and TP53 KO cells in 20 ng/mL EGF, accurate quantification could not be determined due to the increased fluorescence intensity in TP53 KO cells.
To gain insight into the mechanism of how p53 loss leads to centrosome amplification, we performed reverse phase protein array (RPPA) on protein lysates from our cell line panel under physiologic EGF conditions. A complete list of antibodies can be found at www.mdanderson.org/education-and-research/resourcesfor-professionals/scientific-resources/core-facilities-and-services/ functional-proteomics-rppa-core/antibody-lists-protocols/functionalproteomics-reverse-phase-protein-array-core-facility-antibody-listsand-protocols.html. A heat map of the panel was analyzed for differences between parental MCF10A, p53 Kis, and p53 KOs, and six proteins were identified that had changes in expression between the groups of cell lines (SI Appendix, Fig. S4 ). As seen in Fig. 2A , one of the most notable differences between p53 KO cells and parental and p53 KI cells seen in the RPPA data was the decreased expression of phosphorylated NDRG1. NDRG1, also known as DRG1, CAP43, RIT42, RTP, and PROXY-1, was first described as differentiation-related gene 1 (18, 19) . NDRG1 encodes the 46-kDa protein, NDRG1, which is highly conserved among multicellular organisms and is ubiquitously expressed in tissues in response to cellular stress (20) . Prior studies demonstrated that NDRG1 is necessary but not sufficient for p53-mediated apoptosis (21) and may play a role in spindle organization, as NDRG1 has been shown to colocalize with centrosomes (22) . However, NDRG1 as a direct mediator of p53-regulated centrosome homeostasis has not been demonstrated. To correlate and confirm expression of NDRG1 related to abnormal centrosome numbers, cells were cultured in physiologic and maintenance dosages of EGF, harvested for cell lysates, and used for Western blot. As shown in Fig. 2B , under conditions of high EGF, phosphorylated and total amounts of NDRG1 were not significantly different among our panel of cell lines. However, under physiologic doses of EGF and lower proliferation rates, parental MCF10A cells and p53 KI cell lines displayed a dramatic increase in NDRG1 expression by Western blot. In contrast, p53 KO cell lines demonstrated minimal-to-no increase in NDRG1 protein. These data suggest that p53 directly regulates expression of NDRG1 that is governed by the proliferative state of the cell. Of note, phosphorylated NDRG1 and total NDRG1 levels were consistently similar for all experiments, suggesting that differential phosphorylation of NDRG1 was not involved with any functional role between p53 KO and parental cell lines, and that p53 may be directly regulating gene expression of NDRG1.
p53 Increases Under Physiologic Low-Proliferative Conditions and
Binds the Promoter Region of NDRG1. We initially tested whether lowering cell proliferation to physiologic levels would have the expected result of increasing p53 protein levels in MCF10A cells. As shown in Fig. 2C , both MCF10A and p53 KI cells demonstrated relative increases in p53 when placed in physiologic EGF conditions, though the increases were absent as expected in p53 KO cells. We also confirmed that p53 KO cell lines did not demonstrate truncated physiological p53 isoforms (such as delta40p53 at 47 kDa and delta133p53 at 37 kDa) that can arise as a result of N-terminal truncation (SI Appendix, Fig. S5A ). It should be noted that the p53 KI cells showed elevated levels of p53, consistent with this missense mutation's ability to stabilize the p53 protein (23) . Using the same antibody, we next performed ChIP to determine if p53 was bound to a consensus p53 binding site within the NDRG1 promoter and whether this binding increased in physiologic EGF conditions. Quantitative realtime PCR demonstrated that parental cells had significantly increased binding of p53 at the NDRG1 promoter under physiologic EGF conditions relative to high EGF conditions ( Fig. 2D and SI Appendix, Fig. S5B ). As expected, no binding of p53 was observed in the p53 KO cells regardless of EGF conditions. Interestingly, p53 KI cells had a relatively low increase in p53 binding, perhaps indicating that expression of wild-type p53 from the unmodified allele could still mediate some binding at the NDRG1 promoter, despite the presence of the dominant negative R248W allele. Alternatively there may be low-level binding by mutant p53, because the antibody used for ChIP binds both wild-type and mutant p53. Similar to the ChIP data, relative mRNA expression levels of NDRG1 as measured by quantitative real-time PCR in physiologic versus high EGF conditions correlated to p53 binding of the NDRG1 promoter (SI Appendix, Fig. S5C ). Although the p53 KI cells did not exhibit lower protein expression in physiologic EGF, this finding may reflect the increased half-life of NDRG1 protein relative to its mRNA (24) , such that a modest increase in mRNA may lead to sustained NDRG1 protein levels in p53 KI cells. Indeed, SI Appendix, Fig. S6 demonstrates the half-life of NDRG1 in MCF10A and p53 KI cells is ∼20 h. Together, these data support the notion that NDRG1 is a p53-inducible gene.
Homozygous Deletion of TP53 Is Mutually Exclusive with NDRG1
Overexpression in Human Cancers. To further substantiate the link between p53 and NDRG1, we reasoned that human cancers with homozygous deletion of TP53 would be unable to up-regulate NDRG1 gene expression. The cBioPortal database provides gene expression, mutational status, and protein expression from a number of clinical studies including from The Cancer Genome Atlas (TCGA) (25) . Using this database, we analyzed a potential inverse relationship between homozygous loss of TP53 and NDRG1 overexpression across a variety of cancers. To distinguish any differences between TP53 homozygous deletion and TP53 missense mutations, only cancer sets containing both TP53 homozygous deletion and mutations were investigated. Within cBioPortal, 24 datasets contained genomic information on cancers with TP53 homozygous deletions, TP53 missense mutations, and NDRG1 overexpression, representing thousands of patients. When analyzing tumors with TP53 alterations (n = 3,132), (Fig. 3 and SI Appendix, Fig. S7 ), homozygous deletion of TP53 was found in 153 cases with only 6 demonstrating NDRG1 overexpression (3.9%). In contrast, 2,979 cases were found to have TP53 missense mutations, of which 387 demonstrated NDRG1 overexpression (14.0%). This result was highly statistically significant by chi square test (P < 0.000957). These data strongly suggest that homozygous loss of TP53 prevents overexpression of NDRG1, but this is not seen with common TP53 missense mutations. These results support that our in vitro studies are directly relevant to a large and diverse population of human cancers.
NDRG1 Affects Centrosome Homeostasis. Having established the association between NDRG1 expression and p53, and the applicability of this relationship to human cancers, we next sought to determine if NDRG1 directly affected centrosome homeostasis. We first generated NDRG1 knockdown clones with short hairpin RNAi (shRNA) vectors in the parental MCF10A cell line. As seen in Fig. 4A , shRNA against NDRG1 led to a significant decrease in protein levels in both physiologic and high EGF conditions. In addition, we established NDRG1 overexpressing cell lines in p53 KO cells via transfection of a full-length cDNA. Western blot demonstrated that NDRG1 p53 KO overexpressing cells had high levels of NDRG1 in physiologic EGF conditions (Fig. 4A ). These cell lines were then subjected to centrosome analyses. As shown in Fig. 4B , knockdown of NDRG1 in parental p53 wild-type cells demonstrated an increase in centrosomes, whereas NDRG1 overexpression in p53 KO cells resulted in a statistically significant decrease in centrosome numbers. Although our in silico analysis in thousands of human tumors supports the notion that NDRG1 expression is mediated by p53, we wished to determine if these results were generally applicable and therefore repeated these studies using a very different cell line, HCT116. This is a human colorectal cancer cell line with a microsatellite instability phenotype, and p53 KO cells have been previously described (26) . We generated NDRG1 knockdown cells with shRNA in parental p53 wild-type HCT116 cells, as well as NDRG1-overexpressing cells in HCT116 p53 KO cells akin to our MCF10A cell line panel and verified protein expression by Western blot (Fig. 4C and SI Appendix, Fig. S8 ). It should be noted that we could not control proliferation of HCT116 cells even with serum-free conditions similar to the past studies (27) . As such, we could detect only a slight reduction in NDRG1 protein in HCT116 p53KO cells. Nonetheless, HCT116 cells still had a significant increase in centrosome amplification relative to controls, which may suggest other mediators of centrosome formation in this cancer cell line. However, as demonstrated in Fig. 4D , knockdown of NDRG1 in HCT116 parental cells led to a modest but significant increase in centrosome number, whereas overexpression of NDRG1 in HCT116 p53 KO cells led to a dramatic decrease in centrosome amplification compared with p53 KO cells. Representative images for both cell lines are shown in Fig. 4E . These data confirm our results in MCF10A cells and demonstrate that the level of NDRG1 directly regulates centrosome homeostasis. A potential interaction between NDRG1 and γ-tubulin has been previously reported as both proteins are present within the same fraction in cosedimentation assays (22) . To confirm that NDRG1 directly interacts with centrosome assembly and mitotic division in vitro, a proximity ligation assay (PLA) was carried out with antibodies against NDRG1 and γ-tubulin. PLA relies upon antibody detection of proteins and if the antibodies are within 40 nm of one another, then ligation of PLA probes occurs, followed by amplification and fluorescence probe detection in situ. As shown in Fig. 5, MCF10A , p53 KI, and p53 KO demonstrated positive signals relative to the provided negative controls in physiologic EGF conditions. However, signals were reduced in intensity and number in p53 KO cells. Interestingly, numerous positive fluorescence signals were identified throughout the cells, suggesting that NDRG1 and γ-tubulin are continuously associated throughout the cell cycle and are not limited to the centrosomes. To confirm these observations, coimmunoprecipitation was carried out. Unfortunately, attempts at coimmunoprecipitation in MCF10A cells could not technically be performed, likely due to the high amount of protein needed for coimmunoprecipitation studies. However, to further verify that NDRG1 and γ-tubulin can physically associate, we overexpressed NDRG1 in HEK293T cells to model this potential interaction. Immunoprecipitation of γ-tubulin in NDRG1-overexpressing but not empty vector cells showed increased binding of NDRG1 to γ-tubulin (SI Appendix, Fig. S9A ). Loading controls exhibited equivalent levels of γ-tubulin, regardless of NDRG1 overexpression, suggesting the increased levels were the direct result of increased binding between NDRG1 and γ-tubulin. Together, these results suggest that NDRG1 and γ-tubulin physically interact throughout the cell cycle, and therefore NDRG1 levels could directly mediate normal versus abnormal centrosome numbers.
Discussion
TP53 is the most altered tumor suppressor gene in human cancers. It is clear after decades of research that p53 has many roles in both normal and cancer cells, and that common missense mutations have distinct functional consequences compared with complete loss of p53, though both are found in human cancers. Despite numerous studies, there remain areas of uncertainty as to p53's role as the "guardian of the genome" in maintaining genomic stability. Using a panel of isogenic cell lines, our study provides new mechanistic insights into how p53 regulates the centrosome via NDRG1, depending on the proliferative status of the cell, and helps reconcile past conflicting studies regarding p53, centrosome homeostasis, and aneuploidy. Contradictory data on whether loss of p53 function leads to aneuploidy and/or CIN likely are due to differences in cell lines and models used to study these phenotypes (10, 16) . Furthermore, as demonstrated here, p53 missense mutations have a profoundly different effect than homozygous deletion on a variety of cellular functions, and past studies have varied in the methods used to inactivate p53. In addition, prior work using p53 null mouse embryonic fibroblasts suggested that p53 does indeed directly regulate centrosome homeostasis and subsequently aneuploidy (28) , whereas other reports refute this notion (29) . We propose that p53 does not directly alter CIN, as missense mutations did not have appreciable increase in CIN. Further, we speculate that loss of p53 does not directly affect CIN as only one of two p53 KO clones, KO2, demonstrated significantly elevated CIN and an increased aneuploid karyotype (10) , suggesting that CIN in this clone resulted from secondary genetic events. Consistent with this notion, HCT116 p53 KO cells also do not display CIN, though they do tend to become tetraploid (16) . However, our data provide a model whereby loss of p53, but not mutation, leads to abnormal centrosome amplification with resultant aneuploidy, specifically during low, yet physiologically relevant levels of proliferation. As most cell lines in culture are in a highly proliferative state, including HCT116, centrosome amplification and aneuploidy may or may not be seen, depending on the proliferative index and status of A proximity ligation assay (PLA) was performed using antibodies against NDRG1 and γ-tubulin as described in SI Appendix, SI Materials and Methods. Shown are in situ signals (red) of NDRG1 and γ-tubulin association as determined by their proximity to each other within 40 nm. Nuclear DAPI staining is also shown (blue).
NDRG1 protein levels, as demonstrated in this study. The ability to precisely control MCF10A proliferation using varying doses of EGF allowed us to identify this property in p53 null cells. Moreover, the striking inverse correlation between homozygous loss of TP53 and overexpression of NDRG1 using the cBioPortal database, strongly supports that our model is applicable to human cancers. Although it is arguable that cancers are hallmarked by a high proliferation index, perhaps questioning our model's relevance, many human cancers are in fact known to have a low proliferation rate, particularly in early stage disease. For example, the majority of estrogen receptor positive breast cancers display very low rates of proliferation as measured by K i -67 staining. In addition, because loss of p53 is an early event in some tissue types with low proliferation rates, our model provides an explanation as to how loss of p53 under conditions of low cell proliferation could provide the necessary genomic instability that results in subsequent alterations and ultimately leads toward a more aggressive cancer phenotype.
This work also provides a previously unidentified mechanistic link between p53, NDRG1, centrosome homeostasis, and maintaining genome stability (SI Appendix, Fig. S9B ). We propose that loss of p53 is more than a "permissive" event that allows cells with damaged DNA to continue through the cell cycle leading to mutations and aneuploidy. Instead our data suggest that loss of p53 in cells that are undergoing low proliferation fail to up-regulate NDRG1, a putative p53-inducible gene. In turn, this inability to increase NDRG1 expression dysregulates normal centrosome homeostasis, resulting in supernumerary centrosomes with resultant aneuploidy. Although we show that NDRG1 interacts with γ-tubulin, a principal component of the centrosome, we do not yet know how lower levels of NDRG1 during low proliferative states affects centrosome homeostasis. However, it is tempting to speculate that NDRG1 normally sequesters γ-tubulin under low proliferative states such that only the proper amount is available for a normal number of centrosomes to be synthesized. In the absence of p53, NDRG1 is not appropriately increased, leading to excess γ-tubulin and increased numbers of centrosomes with resultant aneuploidy. This model is supported by our PLA results examining the association of NDRG1 and γ-tubulin in p53 KO versus parental and p53 KI cell lines.
In conclusion, we have identified that loss of p53 leads to a distinct form of genomic instability mediated by abnormal centrosome numbers, specifically under conditions of low cell proliferation. We propose that these results could have potential translational implications as cancers with complete loss of p53 may have a form of genomic instability that may be "turned off" by paradoxically administering mitogens that induce a higher rate of proliferation. As genomic instability is thought to be the driver of clonal evolution and drug resistance, this provocative strategy could potentially allow for use of cytotoxic therapies that are currently thought to be less effective for cancers with a low proliferative index, yet may provide improved outcomes due to prevention of drug-resistant clones.
Materials and Methods
Cell Culture, Plasmids, and Transfections. Cell lines, overexpression cDNAs, shRNA constructs, and gene targeting with AAV and their use have been previously described (13, 30) .
Cell Proliferation and Clonogenic Assays. Cell proliferation and clonogenic assays were performed using cell counters and colorimetric assays as previously described (13, 30) .
Matrigel and Soft Agar Assays. Matrigel and soft agar assays were done in sixwell plates as previously described (13, 30) and acini and colonies were assessed at indicated time points.
FISH. FISH assays were performed as previously described (30) using indicated gene probes.
In Silico Data Analysis. Human cancer sample data were generated using cBioPortal (25) .
Additional methods are provided in SI Appendix, SI Materials and Methods.
